Kisspeptin-10
Kisspeptin-10 is a synthetic decapeptide fragment of kisspeptin studied as a tool for probing the hypothalamic-pituitary-gonadal axis and gonadotropin (LH/FSH) release; research protocols typically use 125 mcg daily subcutaneously.
It has been studied as a research tool for probing the hypothalamic-pituitary-gonadal axis, including reproductive and hormonal signaling, gonadotropin (LH/FSH) release, and libido-related research.
Kisspeptin-10 (KP-10) is a synthetic decapeptide corresponding to the conserved C-terminal fragment (residues 112-121) of kisspeptin-54/metastin, the neuropeptide encoded by the KISS1 gene. It is the minimal sequence required for receptor activation. Research has characterized it as a potent agonist of the kisspeptin receptor KISS1R (also known as GPR54), a G-protein-coupled receptor expressed on hypothalamic GnRH neurons.
Binding has been studied as an upstream trigger of gonadotropin-releasing hormone (GnRH) secretion, which in turn has been associated with downstream release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, positioning kisspeptin as a key regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Human studies have reported dose-dependent increases in serum LH and changes in LH pulse frequency following intravenous administration. Kisspeptin-10 is not FDA-approved; it is handled as a research compound, and related kisspeptin analogs remain investigational.
In published human research it has most often been administered intravenously as a bolus or continuous infusion (e.g., bolus doses on the order of ~1 microgram/kg, or infusions of ~1.5-4 micrograms/kg per hour) to study acute LH responses, and dosing in non-clinical research settings is not standardized.
Research using intravenous bolus dosing reported a rapid, dose-dependent rise in serum LH, with peak LH concentrations observed around 30 minutes after administration.
In HPG-axis and reproductive research it is sometimes examined alongside or compared with longer-acting kisspeptin-54 and against GnRH, and discussed in the context of fertility-focused protocols rather than as a fixed stack.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.